Compare Stocks: BMEA, EIKN, KYTX, and ARCT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$12.03 -4.6%	$13.00	$5.50 ▼ $24.17	$358.42M	2.48	821,396 shs	464,148 shs
BMEA Biomea Fusion	$1.26 -7.4%	$1.53	$0.87 ▼ $2.24	$98.58M	-0.28	2.10 million shs	7.85 million shs
EIKN Eikon Therapeutics	$6.72 -7.4%	$9.53	$6.71 ▼ $17.40	$393.24M	N/A	660,700 shs	406,707 shs
KYTX Kyverna Therapeutics	$5.77 -7.1%	$7.54	$5.76 ▼ $13.67	$384.05M	2.06	996,770 shs	1.24 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	-4.60%	-7.46%	-18.33%	+88.26%	-37.96%
BMEA Biomea Fusion	-7.35%	+0.80%	-27.59%	-2.33%	-23.64%
EIKN Eikon Therapeutics	-7.44%	-10.52%	-24.83%	-31.71%	+671,999,900.00%
KYTX Kyverna Therapeutics	-7.09%	-6.33%	-20.52%	-25.84%	-16.74%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$12.03 -4.6%	$13.00	$5.50 ▼ $24.17	$358.42M	2.48	821,396 shs	464,148 shs
BMEA Biomea Fusion	$1.26 -7.4%	$1.53	$0.87 ▼ $2.24	$98.58M	-0.28	2.10 million shs	7.85 million shs
EIKN Eikon Therapeutics	$6.72 -7.4%	$9.53	$6.71 ▼ $17.40	$393.24M	N/A	660,700 shs	406,707 shs
KYTX Kyverna Therapeutics	$5.77 -7.1%	$7.54	$5.76 ▼ $13.67	$384.05M	2.06	996,770 shs	1.24 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	-4.60%	-7.46%	-18.33%	+88.26%	-37.96%
BMEA Biomea Fusion	-7.35%	+0.80%	-27.59%	-2.33%	-23.64%
EIKN Eikon Therapeutics	-7.44%	-10.52%	-24.83%	-31.71%	+671,999,900.00%
KYTX Kyverna Therapeutics	-7.09%	-6.33%	-20.52%	-25.84%	-16.74%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	2.67	Moderate Buy	$22.00	82.88% Upside
BMEA Biomea Fusion	2.71	Moderate Buy	$9.00	614.29% Upside
EIKN Eikon Therapeutics	2.50	Moderate Buy	$25.00	272.02% Upside
KYTX Kyverna Therapeutics	2.86	Moderate Buy	$29.00	402.60% Upside

Current Analyst Ratings Breakdown

Latest BMEA, EIKN, KYTX, and ARCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	ARCT Arcturus Therapeutics	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$13.00 ➝ $19.00
10/7/2026	BMEA Biomea Fusion	Brookline Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy
9/30/2026	BMEA Biomea Fusion	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
9/28/2026	BMEA Biomea Fusion	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/25/2026	KYTX Kyverna Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$25.00
9/25/2026	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/25/2026	KYTX Kyverna Therapeutics	Benchmark Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/24/2026	ARCT Arcturus Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
9/24/2026	ARCT Arcturus Therapeutics	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$23.00 ➝ $20.00
9/24/2026	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Neutral ➝ Buy	$8.00 ➝ $20.00
9/23/2026	KYTX Kyverna Therapeutics	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$82.03M	4.17	N/A	N/A	$7.53 per share	1.60
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$0.42 per share	N/A
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	$3.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$65.78M	-$3.31	N/A	N/A	N/A	-317.62%	-46.54%	-36.46%	11/9/2026 (Estimated)
BMEA Biomea Fusion	-$61.80M	-$0.29	N/A	N/A	N/A	N/A	-253.73%	-97.91%	11/3/2026 (Estimated)
EIKN Eikon Therapeutics	-$324.25M	-$4.09	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	-$161.31M	-$2.94	N/A	N/A	N/A	N/A	-81.92%	-63.74%	11/11/2026 (Estimated)

Latest BMEA, EIKN, KYTX, and ARCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	KYTX Kyverna Therapeutics	-$0.68	N/A	N/A	N/A	N/A	N/A
11/9/2026	Q3 2026	ARCT Arcturus Therapeutics	-$0.6866	N/A	N/A	N/A	$8.00 million	N/A
11/3/2026	Q3 2026	BMEA Biomea Fusion	-$0.21	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	EIKN Eikon Therapeutics	-$1.61	-$1.63	-$0.02	-$1.63	N/A	N/A
8/11/2026	Q2 2026	KYTX Kyverna Therapeutics	-$0.6783	-$0.63	+$0.0483	-$0.63	N/A	N/A
8/7/2026	Q2 2026	ARCT Arcturus Therapeutics	-$0.9964	-$0.84	+$0.1564	-$0.84	$3.11 million	$2.96 million
8/5/2026	Q2 2026	BMEA Biomea Fusion	-$0.2235	-$0.12	+$0.1035	-$0.12	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	5.88	5.88
BMEA Biomea Fusion	N/A	3.47	3.47
EIKN Eikon Therapeutics	N/A	9.89	9.89
KYTX Kyverna Therapeutics	0.15	9.06	9.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
BMEA Biomea Fusion	96.72%
EIKN Eikon Therapeutics	N/A
KYTX Kyverna Therapeutics	18.08%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	17.80%
BMEA Biomea Fusion	10.60%
EIKN Eikon Therapeutics	N/A
KYTX Kyverna Therapeutics	17.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	111	28.42 million	23.36 million	Optionable
BMEA Biomea Fusion	37	72.48 million	64.80 million	Optionable
EIKN Eikon Therapeutics	384	54.17 million	N/A	N/A
KYTX Kyverna Therapeutics	149	61.84 million	50.96 million	Optionable

BMEA, EIKN, KYTX, and ARCT Headlines

Recent News About These Companies

Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026

October 7, 2026 | globenewswire.com

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Stock Has Consensus Price Target of $29.00 According to Analysts

October 3, 2026 | americanbankingnews.com

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Stock Rated "Moderate Buy" by Sell-Side Brokerages

October 3, 2026 | marketbeat.com

HEALTH ROUNDS-Appendix removal linked with lower colon cancer risk in study

October 2, 2026 | marketscreener.comM

Bank of America Corp DE Makes New Investment in Kyverna Therapeutics, Inc. $KYTX

October 1, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Aethlon Medical (AEMD) and Kyverna Therapeutics, Inc. (KYTX)

September 25, 2026 | theglobeandmail.com

KYTX stock reverses gains after one-year cell therapy trial data but CEO says disease burden justifies a premium price

September 25, 2026 | msn.com

Kyverna's miv-cel shows durable one-year benefit in stiff person syndrome and myasthenia gravis

September 25, 2026 | thepharmaletter.comT

Why Kyverna Therapeutics, Inc.’s (KYTX) Stock Is Down 5.01%

September 25, 2026 | aaii.comA

KYTX stock reverses gains after one-year cell therapy trial data — but CEO says disease burden justifies a premium price

September 24, 2026 | msn.com

Kyverna stock jumps on positive one-year therapy data

September 24, 2026 | finance.yahoo.com

Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials Transcript

September 24, 2026 | seekingalpha.com

One-Year Benefits Sustain Momentum For Kyverna's Autoimmune CAR-T Therapy; Stock Up

September 24, 2026 | rttnews.com

Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized ...

September 24, 2026 | finance.yahoo.com

Kyverna Reports One-Year Miv-Cel Data From SPS and gMG Trials

September 24, 2026 | finance.yahoo.com

Kyverna Reports Positive One-Year Data for Miv-Cel

September 24, 2026 | tipranks.com

Kyverna Therapeutics Reports Durable One-Year SPS and Up to 1.5-Year gMG Data for Miv-Cel

September 24, 2026 | quiverquant.comQ

Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis

September 24, 2026 | globenewswire.com

Kyverna Therapeutics, Inc. (KYTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14, 2026 | seekingalpha.com

Wells Fargo Keeps Their Buy Rating on Kyverna Therapeutics, Inc. (KYTX)

September 13, 2026 | theglobeandmail.com

Kyverna Therapeutics to Present at Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMEA, EIKN, KYTX, and ARCT Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$12.03 -0.58 (-4.60%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$12.16 +0.13 (+1.08%)

As of 07:43 AM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Biomea Fusion NASDAQ:BMEA

$1.26 -0.10 (-7.35%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$1.02 -0.24 (-19.05%)

As of 07:52 AM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Eikon Therapeutics NASDAQ:EIKN

$6.72 -0.54 (-7.44%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$6.90 +0.18 (+2.65%)

As of 07:02 AM Eastern

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers. Our Chair and Chief Executive Officer, Dr. Roger M. Perlmutter, M.D., Ph.D., and our Chief Medical Officer, Dr. Roy Baynes, M.D., Ph.D., together have a proven track record of identifying, developing, and commercializing some of the most impactful drugs ever brought to market, including pembrolizumab, currently the world’s best-selling oncology therapeutic and arguably the most important anti-neoplastic agent ever introduced into clinical practice. While Drs. Perlmutter and Baynes’ track records do not provide a guarantee of future clinical success, and any products developed by us may not achieve the regulatory or commercial success of products that Drs. Perlmutter and Baynes were previously involved in developing, their experience provides valuable insight and strategic guidance to our drug development efforts. Our broader leadership team consists of former senior leaders at global pharmaceutical companies, who have successfully collaborated across several decades on the discovery, development, and commercialization of over 100 new molecular entities. Our strategy centers around deploying our technology platform, including our proprietary single molecule tracking, or SMT, system, to develop internally-derived novel therapies, while also leveraging the deep expertise of our management team to opportunistically in-license promising assets. Our most advanced product candidate, EIK1001, a toll-like receptor, or TLR, 7/8 dual-agonist, is currently in a global Phase 2/3 registrational trial in combination with pembrolizumab for the treatment of patients with advanced melanoma. This Phase 2/3 trial is designed to proceed to completion, subject to interim analysis by a data monitoring committee, and to form the basis for registration. We are also evaluating EIK1001 in combination with both pembrolizumab and histology appropriate chemotherapy for the treatment of patients with non-small cell lung cancer, or NSCLC, in a Phase 2 trial, as well as a Phase 2/3 registrational trial for which we recently initiated site selection. We are also conducting Phase 1/2 trials of each of our selective PARP1 inhibitor product candidates, EIK1003 and EIK1004, in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant candidate EIK1004, to address brain metastases and primary brain malignancies. In addition, we have recently initiated a Phase 1/2 trial in patients with advanced solid tumors for EIK1005, our Werner, or WRN, helicase inhibitor that emerged through internal research using our technology platform, which will ultimately be evaluated for the treatment of patients with microsatellite instability-high, or MSI-high, tumors. We were incorporated in Delaware in July 2019. Our principal executive offices are located in Millbrae, California.

Kyverna Therapeutics NASDAQ:KYTX

$5.77 -0.44 (-7.09%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$5.76 0.00 (-0.09%)

As of 07:18 AM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMEA, EIKN, KYTX, and ARCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMEA, EIKN, KYTX, and ARCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMEA, EIKN, KYTX, and ARCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMEA, EIKN, KYTX, and ARCT Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

Biomea Fusion NASDAQ:BMEA

Eikon Therapeutics NASDAQ:EIKN

Kyverna Therapeutics NASDAQ:KYTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMEA, EIKN, KYTX, and ARCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMEA, EIKN, KYTX, and ARCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMEA, EIKN, KYTX, and ARCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMEA, EIKN, KYTX, and ARCT Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

Biomea Fusion NASDAQ:BMEA

Eikon Therapeutics NASDAQ:EIKN

Kyverna Therapeutics NASDAQ:KYTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools